title: Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma.
abstract: A 62-year-old male patient with end-stage renal disease and metastatic renal cell carcinoma (RCC) was referred to our hospital. Sequential targeted therapy consisting of sorafenib, sunitinib, and everolimus was administered, but the patient's disease gradually progressed. Axitinib was subsequently administered at a decreased dose of 6 mg/day for 2 weeks, after which the dose was escalated to 10 mg/day. Axitinib therapy was maintained for a total of 6 months without severe adverse effects. Sequential molecularly targeted drug therapy including axitinib, with careful monitoring, is one possible treatment option for patients with metastatic RCC with renal impairment.
authors: Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi Yamagata, Japan.
authors: Hayato
authors: H
authors: Nishida
authors: Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi Yamagata, Japan.
authors: Hiroki
authors: H
authors: Fukuhara
authors: Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi Yamagata, Japan.
authors: Atsushi
authors: A
authors: Yamagishi
authors: Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi Yamagata, Japan.
authors: Toshihiko
authors: T
authors: Sakurai
authors: Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi Yamagata, Japan.
authors: Tomohiro
authors: T
authors: Shibasaki
authors: Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi Yamagata, Japan.
authors: Hisashi
authors: H
authors: Kawazoe
authors: Department of Urology, Yamagata University Faculty of Medicine, Iida-nishi Yamagata, Japan.
authors: Tomoyuki
authors: T
authors: Kato
authors: Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
authors: Yoshihiko
authors: Y
authors: Tomita
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077784:Axitinib; D018572:Disease-Free Survival; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007191:Indazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000379:methods*; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib
keywords: Metastatic renal cell carcinoma; axitinib everolimus; hemodialysis; renal failure; sorafenib; sunitinib